• Something wrong with this record ?

Minimally Invasive Aortic Valve Replacement with Sutureless Valves: Results From an International Prospective Registry

M. Glauber, L. Di Bacco, J. Cuenca, R. Di Bartolomeo, M. Baghai, D. Zakova, T. Fischlein, G. Troise, G. Viganò, M. Solinas

. 2020 ; 15 (2) : 120-130. [pub] 20191226

Language English Country United States

Document type Journal Article, Multicenter Study, Observational Study

Persistent link   https://www.medvik.cz/link/bmc21012828

OBJECTIVE: To report the early and mid-term results of patients who underwent minimally invasive aortic valve replacement (MI-AVR) with a sutureless prosthesis from an international prospective registry. METHODS: Between March 2011 and September 2018, among 957 patients included in the prospective observational SURE-AVR (Sorin Universal REgistry on Aortic Valve Replacement) registry, 480 patients underwent MI-AVR with self-expandable Perceval aortic bioprosthesis (LivaNova PLC, London, UK) in 29 international institutions through either minithoracotomy (n = 266) or ministernotomy (n = 214). Postoperative, follow-up, and echocardiographic outcomes were analyzed for all patients. RESULTS: Patient age was 76.1 ± 7.1 years; 64.4% were female. Median EuroSCORE I was 7.9% (interquartile range [IQR], 4.8 to 10.9). Median cardiopulmonary bypass and cross-clamp times were 81 minutes (IQR 64 to 100) and 51 minutes (IQR 40 to 63). First successful implantation was achieved in 97.9% of cases. Two in-hospital deaths occurred, 1 for noncardiovascular causes and 1 following a disabling stroke. In the early (≤30 days) period, stroke rate was 1.4%. Three early explants were reported: 2 due to nonstructural valve dysfunction (NSVD) and 1 for malpositioning. One mild and 1 moderate paravalvular leak were reported. In 16 patients (3.3%) pacemaker implantation was needed. Mean follow-up was 2.4 years (maximum = 7 years). During follow-up 5 explants were reported, 3 due to endocarditis and 2 due to NSVD. Follow-up stroke rate was 2.5%. Three structural valve deteriorations not requiring reintervention were reported. Five-year survival was 91.45%. CONCLUSIONS: In this large prospective international registry, MI-AVR with Perceval valve confirmed to be safe, reproducible, and effective in an intermediate-risk population, providing excellent clinical recovery both in early and mid-term follow-up.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012828
003      
CZ-PrNML
005      
20210507102358.0
007      
ta
008      
210420s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/1556984519892585 $2 doi
035    __
$a (PubMed)31875777
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Glauber, Mattia $u 46769 Istituto Clinico Sant'Ambrogio, Milan, Italy
245    10
$a Minimally Invasive Aortic Valve Replacement with Sutureless Valves: Results From an International Prospective Registry / $c M. Glauber, L. Di Bacco, J. Cuenca, R. Di Bartolomeo, M. Baghai, D. Zakova, T. Fischlein, G. Troise, G. Viganò, M. Solinas
520    9_
$a OBJECTIVE: To report the early and mid-term results of patients who underwent minimally invasive aortic valve replacement (MI-AVR) with a sutureless prosthesis from an international prospective registry. METHODS: Between March 2011 and September 2018, among 957 patients included in the prospective observational SURE-AVR (Sorin Universal REgistry on Aortic Valve Replacement) registry, 480 patients underwent MI-AVR with self-expandable Perceval aortic bioprosthesis (LivaNova PLC, London, UK) in 29 international institutions through either minithoracotomy (n = 266) or ministernotomy (n = 214). Postoperative, follow-up, and echocardiographic outcomes were analyzed for all patients. RESULTS: Patient age was 76.1 ± 7.1 years; 64.4% were female. Median EuroSCORE I was 7.9% (interquartile range [IQR], 4.8 to 10.9). Median cardiopulmonary bypass and cross-clamp times were 81 minutes (IQR 64 to 100) and 51 minutes (IQR 40 to 63). First successful implantation was achieved in 97.9% of cases. Two in-hospital deaths occurred, 1 for noncardiovascular causes and 1 following a disabling stroke. In the early (≤30 days) period, stroke rate was 1.4%. Three early explants were reported: 2 due to nonstructural valve dysfunction (NSVD) and 1 for malpositioning. One mild and 1 moderate paravalvular leak were reported. In 16 patients (3.3%) pacemaker implantation was needed. Mean follow-up was 2.4 years (maximum = 7 years). During follow-up 5 explants were reported, 3 due to endocarditis and 2 due to NSVD. Follow-up stroke rate was 2.5%. Three structural valve deteriorations not requiring reintervention were reported. Five-year survival was 91.45%. CONCLUSIONS: In this large prospective international registry, MI-AVR with Perceval valve confirmed to be safe, reproducible, and effective in an intermediate-risk population, providing excellent clinical recovery both in early and mid-term follow-up.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a aortální stenóza $x chirurgie $7 D001024
650    _2
$a bioprotézy $7 D001705
650    _2
$a kardiochirurgické výkony $x metody $7 D006348
650    _2
$a kardiopulmonální bypass $x statistika a číselné údaje $7 D002315
650    _2
$a echokardiografie $x metody $7 D004452
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a srdeční chlopně umělé $7 D006350
650    _2
$a chirurgická náhrada chlopně $x metody $x statistika a číselné údaje $7 D019918
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a miniinvazivní chirurgické výkony $x metody $7 D019060
650    _2
$a prospektivní studie $7 D011446
650    _2
$a protézy - design $x trendy $7 D011474
650    _2
$a registrace $7 D012042
650    _2
$a bezstehová chirurgie $x metody $x statistika a číselné údaje $7 D000071062
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Di Bacco, Lorenzo $u 46769 Istituto Clinico Sant'Ambrogio, Milan, Italy
700    1_
$a Cuenca, Jose $u 16811 CHUAC - Complexo Hospital Universitario, A Coruña, Coruna, Spain
700    1_
$a Di Bartolomeo, Roberto $u 18508 Policlinico Sant'Orsola, Bologna, Italy
700    1_
$a Baghai, Max $u 111990 King's College Hospital, London, UK
700    1_
$a Zakova, Daniela $u 74797 CKTCH, Brno, Czech Republic
700    1_
$a Fischlein, Theodor $u 9211 Klinikum Nürnberg, Paracelsus Medical University, Nuremberg, Germany
700    1_
$a Troise, Giovanni $u 188700 Fondazione Poliambulanza, Brescia, Italy
700    1_
$a Viganò, Giorgio $u 168099 UMCG, Groningen, The Netherlands
700    1_
$a Solinas, Marco $u 267621 Ospedale del Cuore G. Pasquinucci, Massa, Italy
773    0_
$w MED00181718 $t Innovations (Philadelphia, Pa.) $x 1559-0879 $g Roč. 15, č. 2 (2020), s. 120-130
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31875777 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507102357 $b ABA008
999    __
$a ok $b bmc $g 1651072 $s 1133207
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 15 $c 2 $d 120-130 $e 20191226 $i 1559-0879 $m Innovations $n Innovations (Phila) $x MED00181718
LZP    __
$a Pubmed-20210420

Find record

Citation metrics

Archiving options